Pfizer to Acquire Metsera for $7.3 Billion in One of This Year's Largest Pharma Deals

Sep 22, 2025 12:42 CST Updated 12:42

Metsera

Obesity Drug Developer

Pfizer

Pharmaceutical R&D Developer

▲November 6-7The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators Summit Scan to register

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

PharmaCircleMonitoring Shows: Recently, according to a report by the UK's Financial Times, Pfizer is close to reaching a $73 billion deal to acquire Metsera. Pfizer will pay $47.50 per share in cash to Metsera, with an additional $22.50 per share payable if certain specific targets are met, valuing the latter at up to $73 billion (approximately 51.9 billion RMB). The acquisition is expected to be announced as early as September 22, 2025.

Pharmaceutical Circle previously wrote a long articleMetsera. Continuous attention will bring good returns.From $275 Million in Financing to a $25 Billion Market Cap: Is the Rapid Growth a Challenge to the GLP-1 Leader?

Based on a proprietary peptide library of approximately 20,000 Nutritional Stimulating Hormone (NuSH) analog peptides, the company has developed multiple innovative drugs for treating obesity, overweight, and related diseases. The technology platform includes: (1) HALO peptide lipidation technology.: This technology enables peptides to bind simultaneously to albumin and targets, thereby extending the drug half-life to nearly the level of albumin, two to three times longer than other NUSH peptides. This means the drug can be administered once a month, improving tolerability and scalability for production. (2) MOMENTUM Oral Peptide Delivery Technology: This technology can be scaled up for production and offers therapeutic effects at dose levels much lower than competitors' NUSH oral peptides. It combines the manufacturing scale advantages of non-peptide, small-molecule drugs with the efficacy and tolerability akin to injections.

From Innovation to Global Expansion: China's Next "Billion-Dollar Molecule" in Drug Development

References:

Metsera Pharma Data pharma.bcpmdata.com (formerly known as Yaoke Rongyun Data);

; etc.

Scan the QR code immediately to join the PharmRing communication group

Rooted in Shanghai and radiating globally, PharmaCircle serves as a strategic platform for the biopharmaceuticals industry with the mission of "enabling the borderless flow of intelligence and networks." It has established an empowering system covering the entire pharmaceutical industrial chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource connectivity, industry think tanks, and ecosystem communities—it builds the infrastructure for value flow within China's pharmaceutical sector.

Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises’ leapfrog growth.

Like

Share

Point Recommendation